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The UK was one of the first countries to introduce legislation regulating embryo research, and the
British Parliament has taken a liberal view of the field. However, even in the UK, regulation of human
embryonic stem cell (ESC) research has had drawbacks, and the regulatory framework is somewhat
inconsistent and imposes considerable bureaucracy. There are around 33 countries that have
broadly liberal legislation; each has a different view of what is permissible. Only about eight of these
countries have contributed significantly to published research in the field. Paradoxically, in spite of
tight federal restrictions, the USA remains the most productive country in terms of the number and
quality of peer review research publications. But even in our increasingly global society, complex reg-
ulation will become progressively irrelevant and impossible to impose effectively because attitudes
will continue to vary widely in different countries and because of international travel and trade.
Consequently, there is a universal need for scientists to demonstrate their recognition of the ethical
and commercial conflicts that may arise in their research and engage in public debate and dialogue to
ensure responsible activity that benefits their research and reflects the values of society.It is frequently asserted that, promoted by ambition and
the single-minded focus of scientists, science moves
ahead rapidly without taking proper cognizance of public
opinion. This does not seem to have been the case in
the field of human stem cell biology. Scientists have long
recognized the potential that embryonic stem cells
(ESCs) have—it is over 50 years since mammalian ESCs
were first derived (Cole et al., 1966) and 25 years since
their ability to differentiate into different cell types was
described (Evans and Kaufman, 1981). More recently, re-
search and clinical activity in human embryology has been
increasingly under scrutiny. While embryo research has
been rigidly regulated in some parts of Europe, such as
Germany andSwitzerland, inmany parts of theworld there
are no laws against it. In distinction to the USA where
feelings have run high, approximately 33 nations have
relatively liberal legislation in place. In the USA, the NIH
Bioethics Committee approved research on preimplanta-
tion embryos in 1994 (Advisory Committee to the Director,
NIH, 1994) in a proposal that would have allowed a wide
range of experiments on human embryos in the first 2
to 3 weeks of development and the NIH approved funding
for the special creation of embryos in the laboratory.
However, even though human in vitro fertilization (IVF)
treatment pioneered by Robert Edwards and others would
not have been possible without first deliberately creating
embryos for research, these proposals were seen as
controversial. A presidential directive followed, and
federal law in 1996 banned funding ‘‘for the creation of
a human embryo or embryos for research purposes.’’Given that Congress had already sanctioned therapeutic
termination of pregnancy at a much later stage of human
development, this decision seemed inconsistent to
some people. But in the UK, for example, where there
was great research activity in embryology, there was no
legislation at all until 1990. Until then, there is no doubt
that it would have been regarded as justified for UK re-
searchers to attempt to grow cell lines from early human
embryos, whether created specifically for the purpose or
not. Indeed, tacit indications of approval were given by
at least one ethics committee at a major research center,
but the research project was never implemented.
Clearly, one reason why ESC research was not done in
the UK at that time was that, although human IVF embryos
were freely available and patients were very willing to do-
nate them for research (Alder et al., 1986), the production
of ESCs was considered to be a supremely difficult piece
of cookery. And although aborted fetal tissue was easily
obtainable (many British patients were not greatly con-
cerned about its use for research), the recovery of primor-
dial germ cells from such a source is difficult. Modern
methods of therapeutic abortion—mostly the use of the
suction curette—fragment the tissues, making it almost
impossible to identify the tiny germinal cell ridges in all
but very few fetuses.
A more significant reason for this reticence was be-
cause scientists recognized the need to be seen to act
responsibly and not to upset public opinion. It is some-
times forgotten that scientists are altruistic about the
work they do. In Sweden and Finland, for example, thereCell Stem Cell 1, July 2007 ª2007 Elsevier Inc. 27
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ing embryo research, was careful to limit research to
that which they felt was broadly acceptable to the ma-
jority of the public (Hovatta, 2002). In the UK in the
1980s, there were attacks on embryo research by a reli-
gious minority that initially gained considerable political
support. At one point it even seemed possible that all
IVF research might be halted with Enoch Powell’s Un-
born Children (Protection) private member’s Bill (1985),
but this failed after a filibuster in the House of Com-
mons. From that time, until the UK government pro-
duced its own legislation in 1990, scientists and doctors
joined forces to encourage better engagement with the
public. The professionals set up their own regulatory
body, the Voluntary Licensing Authority (VLA), which
was sponsored by the Royal Society, the Medical Re-
search Council, and the professional medical colleges.
Members of the newly established VLA visited all re-
search laboratories and clinical facilities. The VLA li-
censed activities and, without exception, all researchers
submitted to the VLA’s rulings.
The establishment of the VLA was helpful in persuading
some members of the public that scientists and doctors
were working in good faith. But British public opinion
was mostly won over by the evidence that embryo re-
search had resulted in substantial clinical benefits and
that so many newborn babies had improved human hap-
piness. It was also true that, in numerous broadcasts to
the media, the scientists very clearly showed their own
ethical and spiritual values were important in motivating
their work. When statute law was finally being considered,
the favorable vote in the House of Commons in April
1990—a massive two-thirds majority in favor of embryo
research—took place just 2 days after Nature had pub-
lished a paper demonstrating the utility of this research.
The fact that healthy pregnancies had been conceived
after embryo biopsy and preimplantation sexing of em-
bryos to prevent fatal sex-linked genetic disease (Handy-
side et al., 1990) undoubtedly attracted the attention of
many British politicians.
The Human Fertilisation and Embryology Act (1990) es-
tablished an independent regulatory body, the Human
Fertilisation and Embryology Authority (HFEA), which
would report annually to the Secretary of State for Health.
It was to be chaired by a layperson, and only a minority of
those appointed to its board were to be practitioners or
scientists. It had powers to regulate all aspects of IVF,
storage of donor gametes, and embryo research. Parlia-
ment required it to provide information about reproductive
technologies and to keep records of all treatment and re-
search conducted in the UK. The establishment of the
HFEA was initially extremely helpful; but, over 25 years
later, this body seems less appropriate for the work it
has to undertake.
International Perspectives
There remains a powerful distinction between the position
in the USA and that in Britain. In America, a prominent
argument is for the need for ‘‘profound respect’’ for early28 Cell Stem Cell 1, July 2007 ª2007 Elsevier Inc.human embryos (Robertson, 1995). Any attempt to delib-
erately conceive them and then destroy them to serve an-
other’s needs is seen as a breach of this respect by very
many people. This is one reason why such a high profile
has been given to the valuable work with so-called ‘‘adult’’
stem cells. But the potential for adult stem cells to prolifer-
ate in culture and to differentiate into the full range of
cell types is still controversial. However, so far only adult
stem cells have been used for effective medical treat-
ments and the therapeutic use of human ESCs still seems
a long way off.
In the UK, the reaction to embryo research has been
relatively pragmatic and largely more subdued than in
the USA. It has long been widely accepted that various
methods of contraception in general use (such as the
coil, some low-dose oral contraceptives, and the ‘‘morn-
ing-after pill’’) may often only produce their effect some
time after fertilization of the egg has occurred. Moreover,
therapeutic termination of pregnancy has been very freely
available since an act of Parliament in 1967 and has been
accepted with much public approval. Although the law
permits abortion for various carefully delineated cate-
gories, in practice its implementation by most doctors
has been fairly liberal. While Catholics in Britain lined up
firmly against destruction of human embryos, the majority
of British Christians, who are mostly Anglican, have been
fairly supportive of research. The Reverend Gordon Dun-
stan, a distinguished academic moral theologian and an
influential figure in the run-up to the 1990 act, articulated
what he saw as the basic Christian position. He argued
that the claim that absolute protection of the human
embryo is paramount is relatively recent in the Roman
Catholic tradition. Before the 19th century there was a rec-
ognition that ensoulment occurred well after conception.
He cited St Thomas Aquinas who proposed that the em-
bryo was not ‘‘complete’’ until 40 days after conception.
He produced copious evidence that Christian tradition
previously supported the view that the moral status of
the human embryo grew in importance with development
(Dunstan, 1988).
This gradualist view was restated by many parliamen-
tarians in more recent debates on stem cell research in
2001 and 2002 in the House of Lords. The view of the
Lord Bishop of Oxford, a senior Anglican prelate and
a member of the Upper House, was particularly compel-
ling for many people. A Lords Select Committee, which
was chaired by the Bishop of Oxford, stated the following:
‘‘Whilst respecting the deeply held views of those who
regard any research involving the destruction of a human
embryo as wrong and having weighed the ethical argu-
ments carefully, the Committee is not persuaded, espe-
cially in the context of the current law and social attitudes,
that all research on early human embryos should be
prohibited.’’ (Stem Cell Research Committee, 2002b).
This position was accepted by most members of both
Houses of Parliament, when the continuation of human
embryo stem cell research to allow production of ESC
was subsequently passed by an overwhelming two-thirds
majority.
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state’s legal and ethical position mostly follows rabbinical
Talmudic law. IVF for treating human infertility is strongly
supported in Judaism. Using mankind’s ability to promote
health and life (‘‘pikuach nefesh’’ in Jewish law) is broadly
seen as doing God’s purpose and is regarded as of para-
mount importance. The law, however, recognizes that
transferring too many embryos to the uterus, thereby risk-
ing a high-order multiple birth, incurs serious implications
for the mother’s health, as well as risking the well-being of
any babies born as a result of this maneuver. Conse-
quently, many orthodox authorities regard ‘‘spare’’ un-
transferred embryos as ‘‘rodfim’’—‘‘pursuers’’ that might
kill the mother. Self-defense to protect life is permitted in
Jewish law, so destruction of an embryo under such
circumstances is not seen as prohibited. The creation of
embryos specifically for research, though, is regarded
by some authorities as less acceptable. In giving evidence
(Stem Cell Research Committee, 2002a) to the House of
Lords, Dayan Ehrentreu, the Head of the Court of the Chief
Rabbi, London, argued that he felt unready to sanction the
creation of embryos ‘‘specifically for the purposes of
research.’’ But other Jewish authorities, particularly in
Israel, have argued that creating an embryo to transplant
tissue to save the life of an established human beingwould
be acceptable.
This distinction between taking spare embryos that
would otherwise be destroyed after IVF procedures, and
creating embryos de novo, has been heavily debated on
both sides of the Atlantic. When it came to a decision,
the British Parliament did not rule against it. As the moral
philosopher Katrien Devolder (2005) from the University
of Ghent, Belgium pointed out, the compromise position
is weak. To partly summarize Devolder’s position, either
the embryo is intrinsically sacrosanct, in which case no
research is permissible, or it is not.
Opinion in the European Union countries varies signifi-
cantly. Many have a permissive attitude. In Denmark, the
majority of couples favor donating surplus embryos for
research and most prefer this option to giving them to
another couple to allow them to conceive (Bangsboll
et al., 2004). But as ethicists from the University of
Manchester have pointed out, ‘‘the European Union is
a nightmare from the perspective of the ethics and regula-
tion of science’’ (Harris et al., 2005). Predominantly
Catholic countries such as Spain, Portugal, and Poland
are much more reluctant to permit embryo research. In
Germany there is strong disapproval; perhaps the German
people feel the moral weight of this technology, possibly
as an aftermath to events at the time of the Second World
War. Notably, German infertile patients seem broadly sup-
portive of embryo research, but German bioethicists and
medical professionals much less so (Krones et al., 2006).
And the Italian government passed draconian legislation
in February 2004 that greatly hindered much routine prac-
tice of clinical IVF and made egg and embryo donation il-
legal, and research very difficult. However, in a classic Ital-
ian compromise, the import of human ESCs from overseas
is still permitted. The restrictive Italian legislation seemspartly a response to the highly publicized but infamous
pronouncements of Dr. Severino Antinori, who has repeat-
edly claimed to be cloning human embryos in an unspec-
ified clinic (Vogel, 2005).
Maverick pronouncements by various individuals that
they had cloned, or were about to clone, a human embryo
have had massive press coverage and have had an effect
on European public opinion (Watts and Morris, 1999). In
Britain, it is difficult to know how much damage has
been done: for example, various pronouncements from
Dr. Panagiotis Zavos on visits to British shores have
been mostly regarded as laughable—but they attracted
huge media attention and attention from the HFEA, who
might have done better by ignoring them and avoiding
press comment. After all, human reproductive cloning is
illegal in Britain and its practitioners are subject to impris-
onment. In the USA, highly provocative statements about
their prowess at human cloning by Zavos and Antinori and
the bizarre announcements by the Raelian sect may have
had a more serious political effect.
In Singapore, the government established the Bioethics
Advisory Committee (BAC) in December 2000 with a view
to regularizing various aspects of embryo research (Tian
and Leng, 2005). BAC agreed that human ESC research
offered significant therapeutic benefits and stated that
while the human embryo has special status as a potential
human being, this was not equivalent to that of a living per-
son. The respect accorded to the embryo was not seen as
absolute when weighed against the benefits of such re-
search. BAC recommended that, where possible, existing
stem cell lines should be used first and then surplus em-
bryos from IVF treatments. But it did not prohibit the cre-
ation of embryos, as somatic cell nuclear transfer (SCNT)
was considered to be of potential benefit in making trans-
plantable tissues that might not be rejected. It recommen-
ded that strict guidelines should be laid down with regard
to the informed consent of donors and that trading and
commerce in embryos should be outlawed. The Singa-
pore government passed the BAC recommendations
into law in November 2003.
In Sweden, using surplus embryos is permitted provid-
ing the donor gives consent. Any attempts at nuclear
transfer are forbidden, but the government approved
derivation of ESC. In 2002, the Swedish Research Council
earmarked 75 million kronor ($8.1 million) for a stem cell
fund—a decision that was relatively controversial at that
time. Many Swedish biologists felt that it was inappropri-
ate for a country with a relatively small science base to
devote so much funding to one small speculative area of
biology (Vogel, 2002).
Australia has always been at the forefront of reproduc-
tive research andwasearly into the field of IVF. Initially, leg-
islation concerning embryo research varied from state to
state, but in 2002, the federal government granted nearly
$100 million Australian dollars to establish a major re-
search center for stem cell biology in Melbourne. Since
that time, only nine licenses for experimentation with hu-
man embryos have been granted in Australia, of which
four are concerned with research into human ESC. TheCell Stem Cell 1, July 2007 ª2007 Elsevier Inc. 29
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emphasized the pluralistic nature of Australian society
and recognized that a complete consensus regarding the
status of the embryo would be difficult. Although the
most contentious areawas the creation of embryos specif-
ically for research, Lockhart found in favor of this on the
understanding that there should be no intent to create a
person (Sinclair andSchofield, 2007). Consequently, it rec-
ommended that SCNT be permitted under license with
strict guidelines to avoid abuse—partly in response to the
situation that arose with Dr. Hwang’s research in Korea.
In spite of widespread support for the Lockhart recom-
mendations, John Howard, the Prime Minister, opposed
them. It subsequently took a narrow majority in both
Houses of Parliament to pass a privatemember’s Bill intro-
duced by Senator Patterson. This will allow stem cell
research and SCNT to continue from this year in Australia.
Although China is still developing economically, its intel-
lectual and science base is expanding rapidly and the
universities are now pouring out high-quality graduates
on an unprecedented scale. Stem cell research has
been of increasing interest and the regulatory climate is
liberal (Department of Trade and Industry, 2004) as most
Chinese do not consider the human embryo of necessarily
inherent moral value. High-caliber human ESC research
is being undertaken in about seven centers. Although
funding was initially limited, the Chinese Ministry of
Science and Technology has plans to spend as much as
$132 million US dollars in the next 5 years. Given the
relatively liberal attitude of hospital review boards in the
republic of China, it is possible that the Chinese may
attempt translational stem cell work sooner than many
other countries.
In Canada, the government took a long time to enact
legislation. The Royal Commission on New Reproductive
Technologies was published in November 1993 (Royal
Commission on New Reproductive Technologies, 1993).
Thereafter, there were various attempts to bring in legisla-
tion, which mostly failed because of limitations of parlia-
mentary time. It was not until March 2004 that the Assisted
Human Reproduction Act passed its third reading in the
Senate (Canada, 2004). This act, which allows human
ESC research, expressly forbade creation of embryos for
research purposes, germline alteration, commercial activ-
ity with gametes and zygotes, and creating chimeras or
hybrids. The penalty for engaging in prohibited activities
is set at a $500,000 fine and 10 years imprisonment.
Caulfield and Bubela (2007) have argued that this penalty
is highly disproportionate and that the act of Parliament
forbids all experiments with SCNT. But the Canadian
Parliament was more concerned to protect women than
human embryos, and the precise wording of the act, in
prohibiting cloning, would not necessarily prevent all nu-
clear transfer experiments (Mykitiuk et al., 2007). Although
the act prohibits creation of a hybrid ‘‘for the purposes of
reproduction’’ and its transfer ‘‘into either a human being
or a non-human life form,’’ the untested implication seems
to be that creation of tissues in this way may not be illegal
in Canada.30 Cell Stem Cell 1, July 2007 ª2007 Elsevier Inc.Legislative Limitations
The issue of transfer of human nuclei to nonhuman
oocytes is highly topical in Britain. In 2006, two research
groups, one in Newcastle and one at King’s College,
London, applied for a license to make a hybrid, perform-
ing human SCNT into a cow’s egg. A third group led by
Dr. Ian Wilmut, from the team that cloned Dolly the sheep,
also expressed interest in pursuing such an application.
The key reasons for these applications seem to be the
acute shortage of human eggs for stem cell research,
and the opportunity to understand the processes involved
in nuclear reprogramming. There is also the intriguing
possibility that certain genetic diseases could be studied
in detail in tissues derived from such chimeras, if the nu-
clear transfer came from an affected donor—for example,
from a person with motor neuron disease. The idea is not
new; Dr. Sheng’s group in Shanghai undertook human
SCNT into rabbit eggs and generated stem cells that dif-
ferentiated successfully in culture (Chen et al., 2003).
There seems no clear reason why such a procedure
should not be allowed under current British law, and
many scientists believe that it is more ethical to use an an-
imal egg for such work than to use human eggs given the
serious inconvenience to the donor. Nevertheless, the
HFEA, to whom application was made, called for a public
debate before deciding whether to grant licenses for re-
search involving hybrids of human and animal cells
(Mayor, 2007). But meanwhile the Department of Health
in the UK complicated matters by issuing a White Paper
which calls for a ban on this work. So far this has not
yet been debated in Parliament, but a bill will be forthcom-
ing by the summer of 2007, when it is likely that much of
the 1990 Human Fertilisation Embryology Act will be re-
considered. It is difficult to gauge parliamentary opinion
at this stage, but there seems to be a considerable
move in favor of creating such hybrids, the Prime Minister
Tony Blair recently stating that there should be flexibility
with such work.
There seems no possibility that these hybrid embryos
could lead to a life form if transferred to a mammalian
uterus, and certainly the applicants for licenses have
made it clear that there is no intention to study or develop
such embryos once stem cell lines are created from them.
Given the powers of scrutiny that the HFEA have been
given (entry and inspection of laboratories and clinics at
any time and the ability to invoke criminal law) the debate
seems curious.Moreover, there is a precedent for creating
animal-human hybrids which was widely accepted in the
1980s. Until the advent of spermmicroinjection to alleviate
male infertility, it was common practice in most countries,
including Britain, to use the ‘‘Humster’’ test, whereby the
ability of human sperm to penetrate a hamster egg was
routinely used to assess sperm function.
SCNT is not the only way that genetic diseases may be
studied in cultured ESCs. Using preimplantation genetic
diagnosis (PGD) during clinical procedures, Peter
Braude’s group in London identified embryos diagnosed
as homozygous for the Delta F508 cystic fibrosis. These
embryos which would have been otherwise allowed to
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(Pickering et al., 2005). The authors hope this cell line may
help understanding of the pathophysiology of cystic
fibrosis and provide a test bed for new therapies for this
commonmutation. Techniques derived from preimplanta-
tion diagnosis have also been used by Robert Lanza’s
group in Worcester, USA (Klimanskaya et al., 2006).
They established two human ESC lines from 91 biopsied
blastomeres, though no fewer than 19 of the blastomeres
grew ESC-like outgrowths. This work is of interest be-
cause the timing of biopsy was well before blastocyst for-
mation. Biopsy of embryos in this way has been proposed
as one way of avoiding the need to destroy human
embryos to produce ESC, but these workers point out
the procedure should not be recommended outside
PGD. It is yet to be shown whether blastomeres, removed
so early during development, may be more likely to give
rise to ESC lines with epigenetic changes—a concern
which hovers generally about cells in prolonged culture,
given that they might eventually be used for transplanta-
tion after ESC generation and cell differentiation (Allegruci
et al., 2007).
There have been many accusations that human ESC
research is being held up because of bans, public dis-
quiet, or moral outrage in various countries. An important
question is to what extent government regulation, or lack
of it, has either encouraged or inhibited research in various
countries. To help assess this, approximately 2600 cita-
tions on the National Center for Biotechnology Information
PubMed database were reviewed up to April 2007.
Reviews without new research data, editorials, and arti-
cles without an abstract were excluded. Since Thomson
and colleagues first published the derivation of human
ESCs (Thomson et al., 1998), there have been some 530
publications reporting research involving cells derived
from human embryos (Figure 1).
Somewhat surprisingly, despite the presidential prohibi-
tion in the USA, one-third of all publications (159) came
from the USA and a high proportion of these were pub-
lished in journals with the greatest impact factor, suggest-
ing research of the highest quality. The remaining publica-
tions mainly emanated from nine other countries, 55
coming from Israel—a country with one-tenth of the pop-
ulation of the UK, which came third (50 research publica-
tions). Other leading countries were Singapore (33), Korea
(33), China (32), Sweden (28), Australia (23), Canada (13),
and Germany (11). With the exception of Germany, all
these countries have relatively permissive legislation, or
no formal regulation at all. In Germany, there is a complete
ban on all work involving human ESC from German
patients and IVF is heavily regulated. However, German
researchers are, with ethical approval, allowed to import
human ESC lines from other countries for research.
The position in the USA, paradoxically themost produc-
tive country, is complex. The reaction of the strong Chris-
tian religious lobby and the presidential veto initiated in
2001 meant that virtually no federal funding has been
forthcoming. The number of cell lines available to re-
searchers has been limited to those generated before Au-gust 2001. The National Institutes of Health (NIH) has been
able to release 22 approved cell lines that were stored be-
fore the veto, but these lines are of questionable value.
Ware et al. (2006) studied 15 of them, finding that one
was contaminated with mycoplasma. Others lines
showed karyotypic instability, variable cell-cycle time,
and variable cloning and transfection potential. Some
lines contained cells which overgrew, placing selection
pressure on true stem cells. These workers also drew at-
tention to the intellectual property rights to these cell lines,
which could present a problem for researchers. Most of
these human ESC lines had been grown on mouse feeder
layers, a source of a nonhuman sialic acid which would be
immunogenic, making them useless for transplantation
(Martin et al., 2005).
In November 2004, there was substantial breakthrough
in the position in the USA. California Governor Arnold
Schwarzenegger endorsed Proposition 71, which was
subsequently approved by 59% of voters, with bonds be-
ing issued to raise a huge sum: $295 million annually for
10 years for human ESC research in that state. Clearly,
public concern and compassion were key factors in con-
sidering Proposition 71, with the plight of the late Holly-
wood actor, Christopher Reeve, being prominent through
the campaign. Within months of the successful outcome,
several other states, includingMassachusetts, Wisconsin,
New Jersey, and Maryland, gave indication of support for
similar initiatives, which would thus effectively bypass the
federal government ruling. In April 2005 theNational Acad-
emy of Sciences, in a maneuver very reminiscent of that
which established the VLA in the UK 10 years earlier, pro-
duced a set of voluntary ethical guidelines for ESC re-
search (Committee on Guidelines for Human Embryonic
Stem Cell Research, National Research Council, 2005).
The Academy was clearly concerned that the lack of fed-
eral involvement could lead to unscrupulous activity and
a lack of adequate scrutiny of research. The Academy rec-
ommended permitting procedures such as SCNT and the
production of chimeras but imposed a ban on placing hu-
man ESC in the brains or germline of animals. Since that
time there have continued to be initiatives in Congress de-
signed to allow human ESC research. However, though
there is considerable support in both houses, and public
opinion (Leader, 2007) is said to be greatly in favor, the
White House continues to threaten a veto. As the leader
writer in The New York Times suggested: ‘‘There is
a need to free American science from the chains imposed
by the president.’’
The unsatisfactory situation in the USA is a matter for
considerable anxiety, and not just for Americans. It would
be greatly preferable to ensure some proper unbiased fed-
eral control over any scientific research where it concerns
public fears and aspirations. Federal funding for research
is almost certainly the best way of achieving that control.
At present, and in spite of frequent hyperbole, it seems un-
true that US science has greatly suffered from the presi-
dential ban. After all, American scientists have consis-
tently continued to produce the biggest proportion of the
world output in the field (Figure 1B). But financing thisCell Stem Cell 1, July 2007 ª2007 Elsevier Inc. 31
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Publications in Peer Review Journals
(A) Total annual publications from individual
countries.
(B) Cumulative publication totals per country
over time.work by private initiatives or commercial interests raises
substantial concerns. Firstly, there is the obvious criticism
that dangerous work may be going on in secret behind
closed laboratory doors. Secondly, there is always the
risk of conflicts of interest, particularly as universities are
increasingly requiring their academics to protect any intel-
lectual property. Thirdly, there is anxiety that, with com-
mercial pressure, clinical translation of basic science
work could be undertaken too soon and without adequate
safeguards. An accident in this highly publicized field
could have disastrous consequences not only for any
patients involved but also for the standing of stem cell
therapies. It could be irreparably damaging to the interests
of scientific endeavor generally and the public funding that
is needed.32 Cell Stem Cell 1, July 2007 ª2007 Elsevier Inc.Another equally important concern is the issue of raising
expectations. In virtually every country, legislation or fund-
ing of human ESC work has become a public issue and
hugely overstated statements have been made both by
the protagonists of this research and by its opponents.
Scientists and their supporters have frequently argued
so enthusiastically that there is risk of exaggerated expec-
tations of what can be achieved. Republican Michael
Castle, who introduced his Stem Cell Research Enhance-
ment Act of 2005, is reported as saying at a press confer-
ence (Weiss, 2005), ‘‘I firmly believe that ESC research is
the greatest medical hope of the 21st century.’’ While his
support is most welcome, there is a serious risk of raising
expectations; it is worth bearing in mind that to date few
patients if any have clearly benefited from treatment with
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lic support collapse if in due course it feels it has been
badly misled and its taxes squandered?
Within a few months of Proposition 71, the initiative was
criticized with accusations that ‘‘those who pushed hard-
est for the money stand to benefit from it most’’ (Cha,
2005). While the American public rightly show great pride
and trust in the science the USA produces, in many coun-
tries there is growing concern that technology, driven by
commercial interests, may be detrimental to the welfare
of society—for example, offering benefits only to the
wealthiest members of society. In many countries there
is evidence that people are increasingly suspicious that
biotechnology companies are making huge profits that
are not in the public interest. In Britain, public protest at
commercially driven research into genetically modified
crops was so strident that field trials in this important
technology and government support for the work was
completely halted.
In Britain, most funding comes from government and
charitable sources; commercial funding is small. Serious
accusations of financial conflicts of interest are unknown.
Research applications are vigorously scrutinized by the
HFEA, but it is an extremely bureaucratic body with a his-
tory of taking too long over decisions. In order to apply
for a research license involving ESC, scientists currently
have to apply for ethical approval from one of the local re-
search ethics committees (LREC) set up by the Depart-
ment of Health first. These committees consider a wide
range of research applications in all areas of health re-
search, and in many parts of the UK are overloaded. Con-
sequently it can take over 6 months for ethical approval
(longer still if there are initial problems with the wording
of the application), but without this approval the HFEA
will not begin to process an application. Thereafter, there
is usually a minimum of a 3 month delay, and if the HFEA
requires revision of the application or the patient consent
form, the application has to be returned to the LREC, ac-
quiring further delay. The HFEA also sends out all research
license applications for its own peer review. It is not clear
why a double ethical application is needed, nor why peer
review is considered justifiable for applications merely to
undertake research—and most researchers are under-
standably reluctant to announce precisely what their
experiment will involve before applying for funding. An
application for grant support will only be considered
by a research council once HFEA approval has been
considered.
While some attempts are now being made to expedite
this process, it can still take well over a year to obtain a
human ESC research license and to initiate research. Not
surprisingly, few PhD students, the backbone of British
biological research, can afford to wait this long so they
tend to enter other areas of science. So, although British
scientists have published more research papers than
scientists from many other countries, given the size of its
sciencebaseBritain’s record is notparticularly impressive.
Both a regulated and an unregulated system havemajor
difficulties. Ultimately, no regulator can prevent seriousscientific misconduct as was seen in Korea 2 years ago
(Hwang et al., 2005). Although this highly publicized fraud
caused huge angst at the time, it does not seem to have
resulted in much continuing fear about the value and pro-
bity of human ESC research internationally. In Britain, the
HFEA often claims that its monitoring presence allays
public fears about disreputable or unethical activity being
conducted in research establishments. But no good social
science research has been done to demonstrate this; it
could be that a government regulator of this sort may
actually raise public concern—on the principle that if a
regulator is established, there must be some clandestine
activity to hold in check.
One shortcoming of the regulatory system in Britain
has been the failure of the HFEA to disseminate adequate
information and to conduct satisfactory public consulta-
tion. Much of the information it has published in the past
has not been of particularly good quality, and patients
and research workers regularly complain about this.
More important, most public consultation has been done
by launching web-based inquiries—for example, that
of requesting responses to the issue of producing chi-
meras (Human Fertilisation and Embryology Authority,
2007). Inevitably, responses to a web-site by the public
are highly likely to provide a biased impression of public
opinion. In the main, only people strongly opposed to
the research, or strongly in favor of it, may take the trouble
to respond.
Future Prospects
We now live in a global society. Scientific knowledge is
international and is rapidly disseminated with increasing
speed. A ban in one country cannot prevent research pro-
gressing in another. German scientists can import stem
cells from the UK, Italians can buy gametes fromAmerican
web-sites, and Australian scientists did much of their
earlier human ESC work in Singapore. People in China
have a very different view of the status of the embryo
comparedwith the residentsofKentucky. If different states
in the American union cannot agree about what is justified
or ethical, and if opinion in the European Union is so
divided, what chance is there in getting useful international
regulation? But while the total absence of regulation
seems highly undesirable, the imposition of regulation
that cannot be enforced is not an adequate solution either.
What is needed is much more complex. Science is
essential to human health and welfare, but it is not always
regarded as so. If valuable but more controversial areas
such as stem cell science are to be allowed to prosper,
we scientists need to be much more self-critical and
more ready to change. A key place to start must surely
be in our universities,wheremost good science is pursued.
Firstly, we need to teach science students not only to com-
municate better, but how to understand the media, and
engagewith thepublic by listening and responding to legit-
imate concerns. There needs to be more focus on the rou-
tine teaching of ethics; this is a regular part of medical
education, but formal courses on ethics are rare in most
undergraduate science courses. Commercial activity isCell Stem Cell 1, July 2007 ª2007 Elsevier Inc. 33
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Commentaryimportant for scientific progress, but few students are ex-
posed to the pitfalls that it may present and the problems
faced by conflicts of interest. Stem cell science has been
dogged by ludicrous hyperbole, and, as scientists, we
need to be more conscious of the limits of our knowledge
and our ability and indulge less in exaggeration and over-
confidence. Universities should focus more on the nature
of science so that practitioners are brought up with the
understanding that science is as much about uncertainty
as certainty. Perhaps then we might ensure that our re-
search is seen to be pursued with less aggression and
more openness.
The main reason why we pursue stem cell biology is be-
cause we may do some good. Changing the culture in
which science is undertaken is a tall order and will take
a long time.But understanding our role as citizens, respon-
sible to our society internationally as well as nationally, will
be the best way to ensure that this highly promising area
continues to thrive. Stem cell biology is a complex field
of science that has a longway to gobefore it will be of great
benefit. We must remember that while offering so much
promise, this is an area of research that tomanypeople still
seems deeply threatening or morally challenging.
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